We have seen prolonged tumour growth delay in several PDX tumour models with this treatment regimen, including those with either low or high baseline CXCR4 expression,4 suggesting that it may be broadly applicable in patients with cervical cancer. This evidence concerns the gene CXCR4 and cervical cancer.